Patent · US Active

Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease

US10172848B2 · kind B2 · utility

0Cited by

28References

15Claims

0Family size

Assignee

University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventor

David J. Hackam · Pittsburgh, US

Key dates

Filing date	Jun 19, 2013
Grant date	Jan 8, 2019
Priority date	—
Expiry date	Jun 19, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to methods of reducing the risk of occurrence of, and/or treating, necrotizing enterocolitis (“NEC”) or inflammatory bowel disease (“IBD”) comprising administering, to a subject in need of such treatment, an effective amount of a gap junction enhancing agent (“GJEA”), for example a peptide (“GJP”) or peptide analog (“GJPA”). It is based, at least in part, on the discovery that greater functionality of gap junctions between enterocytes increases their rate of migration and reduces the severity of intestinal inflammation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.